



# Proapoptotic effect of nonthermal pulsed ultrasound on prostate cancer cells in a nude mouse model

Maeda, Koki ; Shigemura, Katsumi ; Hayashi, Fuuka ; Kan, Yuki ; Hiraoka, Aya ; Yamaguchi, Atomu ; Ueda, Minori ; Yang, Yong-Ming ; ...

---

**(Citation)**

The Prostate, 83(12):1217-1226

**(Issue Date)**

2023-09

**(Resource Type)**

journal article

**(Version)**

Accepted Manuscript

**(Rights)**

This is the peer reviewed version of the following article: [Maeda, K, Shigemura, K, Hayashi, F, et al. Proapoptotic effect of nonthermal pulsed ultrasound on prostate cancer cells in a nude mouse model. The Prostate. 2023; 83: 1217-1226.], which has been published in final form at [<https://doi.org/10.1002/pros.24581>]. This article m...

**(URL)**

<https://hdl.handle.net/20.500.14094/0100485180>



1 Proapoptotic effect of non-thermal pulsed ultrasound on prostate cancer cells in a nude  
2 mouse model

3

4 Koki Maeda<sup>1</sup>, Katsumi Shigemura<sup>1,2</sup>, Fuuka Hayashi<sup>2</sup>, Yuki Kan<sup>2</sup>, Aya Hiraoka<sup>2</sup>, Atomu  
5 Yamaguchi<sup>3</sup>, Minoru Ueda<sup>4</sup>, Yong-Ming Yang<sup>1</sup>, Noriaki Maeshige<sup>3</sup>, Tooru Ooya<sup>4,5</sup>, Yuzo  
6 Nakano<sup>1</sup>, Masato Fujisawa<sup>1</sup>

7

8 1 Department of Urology, Kobe University Graduate School of Medicine, Kobe, Japan

9 2 Department of International Health, Kobe University Graduate School of Health

10 Sciences, Kobe, Japan

11 3 Department of Rehabilitation Science, Kobe University Graduate School of Health

12 Science, Kobe, Japan

13 4 Department of Chemical Science and Engineering, Graduate School of engineering,

14 Kobe University, Kobe, Japan

15 5 Center for Advanced Medical Engineering Research & Development (CAMED),

16 Kobe University, Kobe, Japan

17

18 Correspondence:

19 Katsumi Shigemura, MD, PhD

20 Department of Urology, Kobe University Graduate School of Medicine,

21 7-5-1 Kusunoki-chou, Chuo-ku, Kobe 650-0017, Japan

22 Email: [katsumi@med.kobe-u.ac.jp](mailto:katsumi@med.kobe-u.ac.jp)

23

24 shortened title: Proapoptotic effect of ultrasound

25 1) data availability statement:

26 The authors agree to Wiley's data availability when published.

27

28 2) funding statement:

29 The authors did not receive support from any organization for the submitted work.

30

31 3) conflict of interest disclosure:

32 The authors have no conflict of interest to disclose.

33

34 4) ethics approval statement:

35 This animal study was approved by the Ethics Committee of Kobe University.

36

37 5) patient consent statement:

38 Not applicable in this study.

39

40 6) permission to reproduce material from other sources:

41 Not applicable in this study.

42

43 7) clinical trial registration:

44 Not applicable in this study.

45

46 **Abstract**

47 **Background**

48 Ultrasound (US) can induce cell injury, and we have previously reported that adjusting  
49 the pulse repetition frequency (PRF) of ultrasound output can induce prostate cancer  
50 cell destruction without causing a rise in the temperature of the irradiated area. In this  
51 study we examined the mechanism of non-thermal ultrasound cell destruction, which  
52 was not fully clarified in our previous reports.

53 **Methods**

54 In vitro, we evaluated post-irradiation cells immediately after treatment and examined  
55 membrane disruption by proliferation assay, LDH assay and apoptosis assay. In vivo,  
56 we injected mice with human LNCaP and PC-3 prostate cancer cells and evaluated the  
57 therapeutic effects of US irradiation by H-E staining and immunostaining.

58 **Results**

59 Proliferation assays showed inhibition at 3 hours post-irradiation independently of PRF  
60 and cell line ( $p < 0.05$ ). Quantitative assessment of apoptosis/necrosis by flow cytometry  
61 showed widely varying results depending on cell type. LNCaP showed an increase in  
62 late apoptosis at 0 h independent of PRF ( $p < 0.05$ ), while PC-3 showed no significant  
63 difference at 0 h. The LDH assay showed an increase in LDH independent of PRF in  
64 LNCaP ( $p < 0.05$  respectively), but no significant difference in PC-3. In vivo, tumor  
65 volume was compared and a significant reduction was observed at 10 Hz for LNCaP  
66 ( $p < 0.05$ ) and 100 Hz for PC-3 ( $p < 0.001$ ) at 3 weeks after the start of irradiation. The  
67 excised tumors were evaluated with Ki-67, Caspase-3, and CD-31 and showed a  
68 significant treatment effect independent of cell type and PRF ( $p < 0.001$  respectively).

69 **Conclusion**

70 Examining the mechanism behind the therapeutic effect of US irradiation revealed that

71 the main effect was achieved by apoptosis induction rather than necrosis.

72

73 Keywords

74 ultrasound irradiation, prostate cancer,

75

## 76 **1. Introduction**

77 Prostate cancer is a very common cancer and the third most common cause of cancer  
78 death in men (1). Treatment methods for prostate cancer generally include active  
79 surveillance, surgery, radiation therapy, and drug therapy including hormone therapy  
80 and anticancer drugs. Each treatment has its advantages and disadvantages. For example,  
81 surgery may cause sexual and urinary dysfunction, and radiation may cause urinary  
82 obstruction and irritation (2). Less invasive treatments with fewer side effects have been  
83 long awaited.

84         Ultrasound (US) is commonly used for examination and diagnosis and is  
85 minimally invasive. It is also widely known that by adjusting the output, it can be used  
86 to damage cells (3). HIFU (High Intensity Focused Ultrasound) has been used clinically  
87 for prostate cancer therapy. HIFU concentrates high-intensity ultrasound waves to  
88 produce thermal and non-thermal effects. The thermal effect produces tissue injury by  
89 necrosis and apoptosis (3). HIFU thermal effects have been reported to cause  
90 complications such as bladder neck/urethral stricture (4). One of the non-thermal effects  
91 is cavitation, where tiny air bubbles are repeatedly generated and collapsed by a brief  
92 change in pressure. The bubbles cause damage to cell membranes by creating shock  
93 waves in the surrounding area when they vanish (5). The cavitation effects also induce  
94 apoptosis and necrosis, the therapeutic effect of US irradiation (3).

95         We have previously reported that optimizing the pulse repetition frequency  
96 (PRF) of non-thermal US has anti-tumor effects on prostate cancer cells (6) and could  
97 enhance therapeutic efficacy in a wild type mouse model (7). Our non-thermal US mode  
98 has an advantage over HIFU by avoiding treatment risks such as stricture, achieving its  
99 anti-tumor effects solely by cavitation. However, we still do not fully understand the

100 mechanism of the anti-tumor effects and apoptosis/necrosis induced by US irradiation.  
101 In particular, US irradiation alone resulted predominantly in apoptosis, but the  
102 proportion of necrosis increased in our wild type mouse model where the immune  
103 system also attacks the cancer cells (7). To reveal the specific effects of US irradiation  
104 on cancer cells, ultrasound has to be applied to cancer cells under immunosuppressive  
105 conditions. In this report, we describe the mechanism by which non-thermal US  
106 irradiation causes tissue damage in an in vivo experiment using immune-suppressed  
107 nude mice and in vitro using a monolayer of prostate cancer cells, focusing on the direct  
108 action of US irradiation on the cell membrane and the apoptotic reaction.

109

## 110 **2. Materials and Methods**

### 111 2.1. Cells

112 To evaluate the therapeutic effects of US irradiation, experiments were performed on  
113 two types of human prostate cancer cells. The androgen-dependent LNCaP prostate  
114 cancer cell line and the androgen-independent PC-3 prostate cancer cell line were  
115 cultured in 35 mm dishes with RPMI-1640 medium (Sigma-Aldrich Japan, Tokyo,  
116 Japan) supplemented with 10% fetal bovine serum (Sigma-Aldrich, Tokyo, Japan) and  
117 1% penicillin-streptomycin (FUJIFILM Wako Pure Chemical Corporation, Osaka,  
118 Japan). Cell cultures were maintained at 37 °C in a 5% CO<sub>2</sub> humidified atmosphere.  
119 Cells were seeded at  $1.0 \times 10^5$  squared cells/dish 24 hours prior to irradiation and then  
120 irradiated on the following day.

121

### 122 2.2 US Irradiation Treatments

123 We irradiated LNCaP and PC-3 with US irradiation (3.0W/cm<sup>2</sup>, 3 MHz, irradiation time:

124 5 minutes, irradiation time rate: 20%) at different PRF of 10 and 100 Hz (a modified  
125 model of the SZ-100, MINATO Medical Science, Osaka, Japan). A lower PRF causes a  
126 longer pulse and higher PRF causes a shorter pulse per irradiation at the same  
127 irradiation time rate. The temperature was kept below 42.5 °C to avoid thermal necrosis.  
128 The observation timing was adjusted for each experimental system.

129

### 130 2.3. Proliferation assay

131 We performed an MTS assay to evaluate the effects of US irradiation performed at each  
132 PRF on the proliferation rate of LNCaP/PC-3. An MTS assay  
133 [3-(4,5-dimethylthiazol-2-yl)-5-(3carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetraz  
134 olum, inner salt] was performed at two time points, 3 hours and 24 hours after US  
135 irradiation. The post-irradiated cells were exposed to MTS for 4 hours and evaluated by  
136 measuring absorbance at 490 nm using a spectrophotometer.

137

### 138 2.4. Imaging Assessment of Membrane Damage

139 We observed live and dead cells using the Cellstain Double Staining Kit (Dojindo  
140 Molecular Technologies, Kumamoto, Japan) and found that US irradiation causes lethal  
141 membrane damage. 24 hours after US irradiation, Calcein-AM staining solution and PI  
142 staining solution were added at concentrations of 2  $\mu\text{mol/l}$  and 4  $\mu\text{mol/l}$ , respectively,  
143 and the cells were incubated for 15 minutes before observation under a fluorescence  
144 microscope BZ-X700 (Keyence, Osaka, Japan). Live cells stained green when excited  
145 with a filter at 490 nm, and dead cells stained red when excited with a filter at 545 nm.

146

### 147 2.5. Apoptosis/Necrosis Assay

148 We evaluated the effects of ultrasound-induced membrane damage on the induction of  
149 apoptosis and necrosis by flow cytometry. The proportion of apoptotic and necrotic cells  
150 was measured by Annexin V and PI dual-staining using the Annexin V-FITC Apoptosis  
151 Detection Kit (Nacalai tesque, Kyoto, Japan). The evaluation was conducted at 0 and 24  
152 hours after US irradiation.

153

#### 154 2.6. LDH assay

155 We hypothesized that membrane damage caused by US irradiation is the mechanism of  
156 cell destruction, and we performed the Cytotoxicity LDH assay Kit-WST (Dojindo  
157 Molecular Technologies, Kumamoto, Japan) to evaluate the degree of membrane  
158 damage observed on cells 24 hours after irradiation.

159

#### 160 2.7. Animal Experiments

161 We conducted animal experiments using nude mice to confirm the antitumor effects of  
162 US irradiation on prostate cancer in vivo. All aspects of the experimental design and  
163 procedure were reviewed and approved by the institutional ethics and animal welfare  
164 committees of Kobe University. Five-week-old Balb/c nu/nu mice were purchased from  
165 CLEA Japan, Inc (Tokyo, Japan).  $1.0 \times 10^6$  cells/mice were administrated at day 0 (n = 5,  
166 respectively). Fourteen days after administration, tumors reached a long diameter of 7  
167 mm and mice were randomly assigned to 3 groups (Control, PRF:10 Hz, 100 Hz). US  
168 irradiation was performed three times a week, and tumor measurement was performed  
169 twice a week. Tumor volumes were expressed by the following formula: (longest  
170 diameter)  $\times$  (shortest diameter) $^2 \times 0.5$ . Finally, mice were sacrificed at day 44 and tumors  
171 were collected. Tumors were fixed and embedded with paraffin.

172

## 173 2.8. Immunohistochemical Staining

174 Immunohistochemical (IHC) staining was performed in an automatic tissue processor  
175 (Bond-Max, Leica Microsystems, Wetzlar, Germany) following the standard protocol.

176 We evaluated three different antibodies with anti-cleaved Caspase-3 as an apoptosis  
177 marker, Ki-67 antibody as a cell proliferation marker, and anti-CD31 primary antibodies  
178 as an angiogenesis marker. H–E staining was also performed to assess the necrotic area  
179 of the tumor.

180

## 181 2.9. Immunohistochemical Analysis

182 The stained slides were observed under a microscope BZ-X700 (Keyence, Osaka,  
183 Japan). For H–E staining, the ratio of necrotic areas to the entire tumor was calculated.  
184 For IHC staining of Ki-67 and Caspase-3, the intensity of staining was evaluated on a  
185 4-point scale of 0 (negative), 1 (weak), 2 (intermediate), and 3 (strong), and the range  
186 was evaluated on a three-point scale of 1 (0–10%), 2 (11–50%), and 3 (50% or more).  
187 The total IHC score was determined by multiplying the frequency and intensity scores  
188 (8). For CD-31, the number of stained blood vessels was counted per field of view, and  
189 the average of five fields of view was measured.

190

## 191 2.10. Statistical analysis

192 Comparisons between two different groups were performed using Student's T-test.  
193 Comparisons between multiple groups were performed using one-way analysis of  
194 variance (ANOVA) followed by the Tukey–Kramer method. Statistical differences  
195 among means were considered significant when  $p < 0.05$ .

196

197 **3. Results**198 3.1. Cell proliferation assay (**Figure 1**)

199 We performed a proliferation assay 3 h and 24 h after US irradiation. At 3 h, both  
200 LNCaP and PC-3 showed a significant decrease in viability at 10 Hz and 100 Hz  
201 (LNCaP: Ctrl; 1.000, 10Hz;  $0.653 \pm 0.063$  ( $p=0.043$ ), 100Hz;  $0.667 \pm 0.071$  ( $p=0.015$ ).  
202 PC-3: Ctrl; 1.000, 10Hz;  $0.808 \pm 0.029$  ( $p=0.039$ ), 100Hz;  $0.778 \pm 0.031$  ( $p=0.032$ )). At 24  
203 hours after US irradiation, only 10 Hz showed a significant difference (LNCaP: Ctrl;  
204 1.000, 10Hz;  $0.628 \pm 0.096$  ( $p=0.035$ ), 100Hz;  $0.938 \pm 0.184$  ( $p=0.676$ ). PC-3: Ctrl; 1.000,  
205 10Hz;  $0.374 \pm 0.099$  ( $p=0.020$ ), 100Hz;  $0.637 \pm 0.010$  ( $p=0.056$ )).

206

207 3.2. Imaging Assessment of Membrane Damage (**Figure 2**)

208 Cells that stain green under a fluorescence microscope are live cells, while cells that  
209 stain red are dead cells. The dead cells in the irradiated group show a pale spread of red  
210 staining around the cells. Dead cells stain red when the PI stain solution enters the  
211 double helix structure of the DNA and turn red, so the spread of staining suggested that  
212 cell contents may have been released due to cell membrane damage.

213

214 3.3. Apoptosis Assay (**Figure 3**)

215 The percentages of early apoptosis, late apoptosis, and necrosis were quantified by flow  
216 cytometry at 0 and 24 hours after US irradiation, respectively. In LNCaP cells, late  
217 apoptosis was significantly increased immediately at 0 hour (10Hz;  $8.40 \pm 0.68\%$  vs ctrl;  
218  $6.07 \pm 0.46\%$  ( $p=0.040$ ). 100Hz;  $11.09 \pm 0.64\%$  vs ctrl;  $8.49 \pm 0.36\%$  ( $p=0.026$ )). 24 hours  
219 later, only 100 Hz showed a significant difference in apoptosis (early apoptosis 100 Hz,

220 23.61±4.73% vs ctrl 8.06±2.80% (p=0.041); late apoptosis 100Hz 18.03±0.64% vs ctrl  
221 9.66±0.23% (p<0.001); total apoptosis 100 Hz 41.64±5.13% vs ctrl 17.71±2.97%  
222 (p=0.015)). In PC-3 cells, no significant difference was observed immediately after  
223 irradiation at either 10 Hz or 100 Hz, and an increase in late apoptosis and necrosis was  
224 only observed at 10 Hz after 24 hours (late apoptosis 10 Hz 11.75±1.13% vs ctrl  
225 7.42±0.37% (p=0.020); necrosis 10 Hz 0.20±0.04% vs ctrl 0.02±0.01% (p=0.013)). We  
226 performed flow cytometry again with the addition of the apoptosis inhibitor, but the  
227 percentage of apoptosis did not decrease and the percentage of necrosis did not increase.

228

#### 229 3.4. LDH assay (Figure 4)

230 The LDH kit was used to evaluate the rate at which the cell contents, LDH, were  
231 released outside the cell by membrane damage. Prior to the experiment, the cell count  
232 was set at 3000 cells/well by measuring high and low controls. Results showed a  
233 significant increase in LDH in LNCaP cells at 10 Hz and 100 Hz compared to controls  
234 (10 Hz 10.89±0.31% (p<0.001), 100 Hz 2.53±0.27% (p=0.033) vs ctrl 0.14±0.55%).  
235 PC-3 showed no significant difference at both 10 Hz and 100 Hz (10 Hz 3.62±0.28%  
236 (p=0.531), 100 Hz 2.61±0.53% (p=0.636) vs ctrl 3.10±0.56%).

237

#### 238 3.6. Animal Experiments (Figure 5)

239 The therapeutic effect of US irradiation was examined on nude mice transplanted  
240 subcutaneously with LNCaP cells and PC-3 cells. Tumor size was significantly reduced  
241 by irradiation at 100 Hz for PC-3 and at 10 Hz for LNCaP. Tumors were removed after  
242 the final irradiation. LNCaP cells in the 10 Hz group and PC-3 cells in the 100 Hz group  
243 were significantly smaller than in the control group (LNCaP: Ctrl, 442.0±166.4 cm<sup>3</sup>; 10

244 Hz,  $282.9 \pm 58.6 \text{ cm}^3$  ( $p=0.033$ ); 100 Hz,  $339.4 \pm 59.7 \text{ cm}^3$  ( $p=0.167$ ). PC-3: Ctrl,  
 245  $532.8 \pm 97.6 \text{ cm}^3$ ; 10 Hz,  $443.5 \pm 104.2 \text{ cm}^3$  ( $p=0.109$ ); 100 Hz,  $313.3 \pm 52.1 \text{ cm}^3$   
 246 ( $p<0.001$ ). In the present study, US irradiation was performed directly on the  
 247 subcutaneously implanted tumor, and no burns or other side effects were observed on  
 248 the skin at the irradiated site.

249

### 250 3.7. H-E Staining, Immunohistochemical Staining (Figures 6, 7)

251 The percentage of tumor necrosis was evaluated by HE staining of the excised tissue  
 252 using the method described above. Both LNCaP and PC-3 showed significant increases  
 253 in necrotic tissue at 10 Hz and 100 Hz (LNCaP: 10 Hz  $16.5 \pm 7.3$  ( $p < 0.001$ ); 100 Hz,  
 254  $16.6 \pm 6.8$  ( $p < 0.001$ ), ctrl,  $6.8 \pm 1.9$ ; PC-3: 10 Hz,  $29.3 \pm 9.5$  ( $p < 0.001$ ); 100 Hz,  $35.8 \pm 7.6$   
 255 ( $p < 0.001$ ); ctrl,  $15.0 \pm 7.9$ ).

256 Immunostaining with Ki-67, Caspase-3, and CD31 was then performed. Ki-67 was  
 257 evaluated as a cell proliferation marker, and Ki-67 expression was significantly  
 258 suppressed at 100 Hz in both LNCaP and PC-3 compared to the control group (LNCaP:  
 259 10 Hz,  $6.4 \pm 1.8$  ( $p < 0.052$ ); 100 Hz,  $6.0 \pm 1.7$  ( $p < 0.002$ ) vs ctrl,  $7.1 \pm 1.6$ . PC-3: 10 Hz,  
 260  $5.4 \pm 1.8$  ( $p < 0.001$ ), 100 Hz,  $4.6 \pm 1.4$  ( $p < 0.001$ ), vs ctrl,  $6.6 \pm 1.4$ ). Caspase-3 was  
 261 evaluated as an apoptosis marker, revealed that while LNCaP results were not  
 262 significantly different at 10 Hz and 100 Hz, PC-3 was significantly elevated at 10 Hz  
 263 and 100 Hz compared to the control group (LNCaP: 10 Hz,  $4.8 \pm 1.0$  ( $p < 0.001$ ); 100 Hz,  
 264  $3.5 \pm 1.4$  ( $p < 0.001$ ); ctrl  $2.3 \pm 0.9$ . PC-3: 10 Hz,  $5.7 \pm 1.7$  ( $p < 0.001$ ); 100 Hz,  $5.4 \pm 1.5$  ( $p$   
 265  $< 0.001$ ); ctrl,  $3.7 \pm 1.5$ ). CD31 was evaluated as a marker of angiogenesis, and LNCaP  
 266 showed no significant difference, but PC-3 showed significantly suppressed expression  
 267 at 10 Hz and 100 Hz (LNCaP: 10 Hz,  $7.9 \pm 2.4$  ( $p < 0.001$ ); 100 Hz,  $8.4 \pm 2.4$  ( $p < 0.001$ );

268 ctrl 11.4±1.8. PC-3: 10 Hz, 62.8±6.2 (p <0.001); 100 Hz, 43.2±13.4 (p <0.001); ctrl  
269 86.80±9.3).

270 We observed Differences in sensitivity to US irradiation between LNCaP and  
271 PC-3. Especially in vitro, LNCaP showed a significantly greater therapeutic effect than  
272 PC-3. On the other hand, in vivo studies have shown similar therapeutic effects in both  
273 cases.

274

#### 275 **4. Discussion**

276 Prostate cancer is the most prevalent malignancy in men and is commonly treated with  
277 active surveillance, surgery, radiation, and hormonal therapy. Many cases of localized  
278 prostate cancer can be cured by radical surgery or radiotherapy, but surgery has  
279 complications such as erectile dysfunction and urinary incontinence, and radiation has  
280 complications such as urinary obstruction, irritation and bleeding in the late stages (2).  
281 Hormone therapy is effective in many patients, but may eventually lead to  
282 castration-resistant prostate cancer (CRPC). Treatment options for CRPC are increasing,  
283 but the prognosis is still poor. (9). A less invasive treatment with a different mechanism  
284 of action than conventional therapy is much desired.

285 Ultrasound is commonly used as an examination device, but it is also used for  
286 treatment by adjusting the ultrasound output. By varying the power, frequency, and PRF  
287 parameters, the ultrasound output produces effects such as tissue injury, apoptosis and  
288 necrosis through thermal and non-thermal effects (3). The thermal effects cause tissue  
289 injury in various ways including apoptosis, necrosis, altered gene expression, and  
290 membrane dysfunction. However, thermal effects may cause irreversible changes to  
291 areas other than the target organs of irradiation, and bladder neck/urethral stricture has

292 been reported as a complication of HIFU (4). The focal area reaches 60 °C to 85 °C,  
293 causing protein coagulation, fusion of cell membranes, and necrosis of tumor cells.  
294 Outside the focal region, the temperature decreases gradually, so the cells are not  
295 subjected to immediate death levels of heat, but they are exposed to temperatures above  
296 40 °C, and most of these cells undergo apoptosis in the days following treatment (10).  
297 US irradiation also has non-thermal effects not related to temperature rise. The  
298 cavitation effects, one of the mechanisms of non-thermal effects, produce shear forces  
299 and pressure changes, release reactive molecules (3) and also induce apoptosis (11).

300         The US irradiation technology we used in this study produces anti-tumor  
301 effects by cavitation, with no thermal effects, by adjusting the ultrasound PRF.  
302 Therefore, unlike HIFU, the possibility of urethral stricture or burns due to temperature  
303 increase are expected to be reduced in clinical application.

304         In general, apoptotic cells do not release their cellular constituents into the  
305 surrounding interstitial tissue (12), whereas in necrosis the cell membrane is disrupted  
306 and cell contents such as nucleus and cytoplasm are released (13). When we observed  
307 cells for several hours after irradiation, our findings were suggestive of apoptosis, such  
308 as reduction of cellular volume and bleb formation (14), and also were suggestive of  
309 necrosis, such as membrane rupture (14) (Fig. 2). In our previous studies using wild  
310 type mouse and syngeneic mouse cancer cells, necrosis was the predominant antitumor  
311 effect (7). The present study confirmed by flow cytometry that necrosis occurred in only  
312 a few cells (Fig. 3), and it was noteworthy that LDH was released extracellularly (Fig.  
313 4). Cell membranes have important function in maintaining cellular homeostasis, and  
314 cavitation has a variety of effects on cell membranes depending on the degree of  
315 ultrasound pressure. At moderate ultrasound pressure, stable cavitation stimulates

316 endocytosis. At higher ultrasound pressures, effects become so intense that they pierce  
317 the cell membrane, known as sonoporation (15), which is also attracting attention as an  
318 intracellular drug delivery method (16). If the pressure is too strong, the damage results  
319 in cell death by necrosis (17). US irradiation itself has been shown to induce apoptosis  
320 (18), and the mitochondrial caspase pathway and reactive oxygen species are thought to  
321 be involved in the mechanism (19). Considering the fact that necrosis is rarely observed  
322 while LDH is elevated (Fig 4), our US irradiation mainly resulted in small pore  
323 formation in the cell membrane, which induced apoptosis.

324         The current results show that LNCaP and PC-3 differ in therapeutic efficacy in  
325 vitro, specifically that PC-3 may be resistant to treatment compared to LNCaP. This  
326 trend has been suggested in previous reports (6). Differences in efficacy by cell type are  
327 observed despite the fact that the treatment mechanism is mechanical stimulation, which  
328 has also been reported for X-ray radiation (20) and HIFU combined with radiotherapy  
329 (21). PC-3 are cells established from bone metastases of CRPC patients, and LNCaP are  
330 cells established from lymph node of androgen-dependent prostate cancer patients. A  
331 difference in cell membranes may have an impact, as the therapeutic mechanism is the  
332 apoptosis-inducing effect of cell membrane disruption.

333         Not only by cell type, but also by time after US irradiation, the therapeutic  
334 effect has been observed to vary. Although the present study was not able to evaluate  
335 why there was a difference in therapeutic effect by time, it has been reported that  
336 hyperthermia therapy shows cytotoxicity and DNA damage within 24 hours after  
337 irradiation, followed by recovery (21). We have observed therapeutic effect in our US  
338 irradiation due to the nonthermal effect, but a similar mechanism is expected in terms of  
339 mechanical stimulation. Further research is needed.

340           Although the PRFs that inhibited tumor growth in this animal study differed by  
341 cell type, immunohistochemistry staining showed apoptosis-inducing and  
342 angiogenesis-inhibiting effects independent of cell type and PRF. PC-3 in particular  
343 showed an increase in the area of necrotic tissue, which may have resulted in a greater  
344 therapeutic effect than the measured tumor size. PC-3 is an androgen-independent  
345 prostate cancer cell difficult to treat in practice, so the possibilities of treatment by US  
346 irradiation could be significant.

347           US irradiation alone in this case was able to inhibit tumor growth, but did not  
348 reduce tumor size. It will be necessary to demonstrate a stronger therapeutic effect for  
349 clinical use. One way to achieve the stronger effect is in combination with immune  
350 checkpoint inhibitors. Prostate cancer is known to be an immunologically "cold" tumor  
351 that does not respond well to immune checkpoint inhibitors. However, Eranki et al.  
352 reported that the combination of HUFU and an immune checkpoint inhibitor showed a  
353 strong antitumor effect in immunologically "cold" neuroglioma (22). Shibin et al. also  
354 reported that the combination of US irradiation and immune checkpoint inhibitors for  
355 melanoma in mice showed enhanced antitumor effects and an abscopal effect that was  
356 therapeutic even for distant metastases (23). We have also shown that combining US  
357 irradiation with a PD-1 antibody enhances the therapeutic effect (7).

358           Another way to increase the effectiveness of our ultrasound technology would  
359 be to create nanobubbles specifically targeted in prostate cancer cells to induce  
360 sonoporation through microbubble collapse upon US irradiation (24), which would act  
361 more specifically on prostate cancer cells and reduce damage to normal cells. Zlitin et al.  
362 reported that creating microbubbles that accumulate in the prostate specific membrane  
363 antigen (PSMA) could improve the detection rate of prostate cancer diagnosis by

364 ultrasound (25). We believe that combining these techniques could potentially improve  
365 the therapeutic effect of our US irradiation.

366         Combining US irradiation with immune checkpoint inhibitors and nanobubbles  
367 may have therapeutic potential not only for localized prostate cancer, but also for CRPC  
368 with metastases. This US irradiation technology could be applied for prostate cancer  
369 treatment in the future, but there are limitations to this study. First, irradiation was  
370 performed by applying the probes directly to the tumor subcutaneously. To irradiate the  
371 prostate, a transrectal method of irradiation is being considered, and the effects on  
372 surrounding normal organs such as the urethra and rectum need to be considered.  
373 Second, we used nude mice to examine the therapeutic effect on human prostate cancer  
374 cells, so we could not fully evaluate the immunological effects of the treatment. We plan  
375 to conduct experiments using mouse prostate cancer cells in the future. Third, in animal  
376 studies tumors are removed at the end of treatment, so changes in tumor size after  
377 treatment is stopped have not yet been confirmed.

378

## 379 **5. Conclusions**

380 The therapeutic effects of non-thermal US irradiation on prostate cancer cells was  
381 demonstrated in vitro and in vivo. We also confirmed that the anti-tumor effect of US  
382 irradiation is mainly due to the induction of apoptosis.

383

## 384 **6. References**

385 1) Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. *CA Cancer J Clin.* 2017  
386 Jan;67(1):7-30.

387 2) Litwin MS, Tan HJ. The Diagnosis and Treatment of Prostate Cancer: A Review.

- 388 JAMA. 2017 Jun 27;317(24):2532-2542.
- 389 3) Shankar H, Pagel PS. Potential adverse ultrasound-related biological effects: a  
390 critical review. *Anesthesiology*. 2011 Nov;115(5):1109-24.
- 391 4) Poissonnier L, Chapelon JY, Rouvière O, Curiel L, Bouvier R, Martin X, Dubernard  
392 JM, Gelet A. Control of prostate cancer by transrectal HIFU in 227 patients. *Eur Urol*.  
393 2007 Feb;51(2):381-7.
- 394 5) Wang X, Ning Z, Lv M, Wu P, Sun C, Liu Y. Transition mechanisms of translational  
395 motions of bubbles in an ultrasonic field. *Ultrason Sonochem*. 2023 Jan;92:106271.
- 396 6) Maeshige N, Kitagawa K, Yamasaki S, Ishii A, Shirakawa T, Yang YM, Sung SY,  
397 Chen KC, Yuan ZM, Shigemura K, Fujisawa M. Can ultrasound irradiation be a  
398 therapeutic option for prostate cancer? *Prostate*. 2020 Sep;80(12):986-992.
- 399 7) Hayashi F, Shigemura K, Maeda K, Hiraoka A, Maeshige N, Ooya T, Sung SY, Yang  
400 YM, Fujisawa M. Combined Treatment with Ultrasound and Immune Checkpoint  
401 Inhibitors for Prostate Cancer. *J Clin Med*. 2022 Apr 27;11(9):2448.
- 402 8) Yamamichi F, Shigemura K, Behnsawy HM, Meligy FY, Huang WC, Li X, Yamanaka  
403 K, Hanioka K, Miyake H, Tanaka K, Kawabata M, Shirakawa T, Fujisawa M. Sonic  
404 hedgehog and androgen signaling in tumor and stromal compartments drives  
405 epithelial-mesenchymal transition in prostate cancer. *Scand J Urol*. 2014  
406 Dec;48(6):523-32.
- 407 9) Terada N, Sawada A, Kawanishi H, Fujimoto T, Magaribuchi T, Chihara I,  
408 Hashimoto K, Sakurai T, Shimizu Y, Uegaki M, Nakashima M, Narita S, Kubota M,  
409 Yamada Y, Tohi Y, Okabe K, Yatsuda J, Kamoto T. The efficacy of sequential therapy  
410 with docetaxel and cabazitaxel for castration-resistant prostate cancer: A retrospective  
411 multi-institutional study in Japan. *Int J Urol*. 2022 Nov 14.

- 412 10) Hoogenboom M, Eikelenboom D, den Brok MH, Veltien A, Wassink M, Wesseling  
413 P, Dumont E, Fütterer JJ, Adema GJ, Heerschap A. In vivo MR guided boiling  
414 histotripsy in a mouse tumor model evaluated by MRI and histopathology. *NMR*  
415 *Biomed.* 2016 Jun;29(6):721-31.
- 416 11) Stanton MT, Ettarh R, Arango D, Tonra M, Brennan PC. Diagnostic ultrasound  
417 induces change within numbers of cryptal mitotic and apoptotic cells in small  
418 intestine. *Life Sci.* 2001 Feb 16;68(13):1471-5.
- 419 12) Elmore S. Apoptosis: a review of programmed cell death. *Toxicol Pathol.* 2007  
420 Jun;35(4):495-516.
- 421 13) Vandenabeele P, Galluzzi L, Vanden Berghe T, Kroemer G. Molecular mechanisms  
422 of necroptosis: an ordered cellular explosion. *Nat Rev Mol Cell Biol.* 2010  
423 Oct;11(10):700-14.
- 424 14) Kroemer G, Galluzzi L, Vandenabeele P, Abrams J, Alnemri ES, Baehrecke EH,  
425 Blagosklonny MV, El-Deiry WS, Golstein P, Green DR, Hengartner M, Knight RA,  
426 Kumar S, Lipton SA, Malorni W, Nuñez G, Peter ME, Tschopp J, Yuan J, Piacentini  
427 M, Zhivotovsky B, Melino G; Nomenclature Committee on Cell Death 2009.  
428 Classification of cell death: recommendations of the Nomenclature Committee on  
429 Cell Death 2009. *Cell Death Differ.* 2009 Jan;16(1):3-11.
- 430 15) Kooiman K, Roovers S, Langeveld SAG, Kleven RT, Dewitte H, O'Reilly MA,  
431 Escoffre JM, Bouakaz A, Verweij MD, Hynynen K, Lentacker I, Stride E, Holland  
432 CK. Ultrasound-Responsive Cavitation Nuclei for Therapy and Drug Delivery.  
433 *Ultrasound Med Biol.* 2020 Jun;46(6):1296-1325.
- 434 16) Deprez J, Lajoinie G, Engelen Y, De Smedt SC, Lentacker I. Opening doors with  
435 ultrasound and microbubbles: Beating biological barriers to promote drug delivery.

- 436 Adv Drug Deliv Rev. 2021 May;172:9-36.
- 437 17) Prentice, P., Cuschieri, A., Dholakia, K., Mark Prausnitz, Paul Campbell. Membrane  
 438 disruption by optically controlled microbubble cavitation. *Nature Phys* 1, 107–110  
 439 (2005).
- 440 18) Ashush H, Rozenszajn LA, Blass M, Barda-Saad M, Azimov D, Radnay J, Zipori D,  
 441 Rosenschein U. Apoptosis induction of human myeloid leukemic cells by ultrasound  
 442 exposure. *Cancer Res.* 2000 Feb 15;60(4):1014-20.
- 443 19) Honda H, Kondo T, Zhao QL, Feril LB Jr, Kitagawa H. Role of intracellular  
 444 calcium ions and reactive oxygen species in apoptosis induced by ultrasound.  
 445 *Ultrasound Med Biol.* 2004 May;30(5):683-92.
- 446 20) Adamczuk GM, Humeniuk E, Adamczuk K, Madej-Czerwonka B, Dudka J.  
 447 Disruption of mitochondrial function augments the radiosensitivity of prostate cancer  
 448 cell lines. *Ann Agric Environ Med.* 2023 Mar 31;30(1):65-76.
- 449 21) Zhang X, Bobeica M, Unger M, Bednarz A, Gerold B, Patties I, Melzer A, Landgraf  
 450 L. Focused ultrasound radiosensitizes human cancer cells by enhancement of DNA  
 451 damage. *Strahlenther Onkol.* 2021. Aug; 197(8):730-743.
- 452 22) Eranki A, Srinivasan P, Ries M, Kim A, Lazarski CA, Rossi CT, Khokhlova TD,  
 453 Wilson E, Knoblach SM, Sharma KV, Wood BJ, Moonen C, Sandler AD, Kim PCW.  
 454 High-Intensity Focused Ultrasound (HIFU) Triggers Immune Sensitization of  
 455 Refractory Murine Neuroblastoma to Checkpoint Inhibitor Therapy. *Clin Cancer Res.*  
 456 2020 Mar 1;26(5):1152-1161.
- 457 23) Qu S, Worlikar T, Felsted AE, Ganguly A, Beems MV, Hubbard R, Pepple AL,  
 458 Kevelin AA, Garavaglia H, Dib J, Toma M, Huang H, Tsung A, Xu Z, Cho CS.  
 459 Non-thermal histotripsy tumor ablation promotes abscopal immune responses that

- 460 enhance cancer immunotherapy. *J Immunother Cancer*. 2020 Jan;8(1).
- 461 24) Chen X, Leow RS, Hu Y, Wan JM, Yu AC. Single-site sonoporation disrupts actin  
462 cytoskeleton organization. *J R Soc Interface*. 2014 Mar 26;11(95):20140071.
- 463 25) Zlitni A, Yin M, Janzen N, Chatterjee S, Lisok A, Gabrielson KL, Nimmagadda S,  
464 Pomper MG, Foster FS, Valliant JF. Development of prostate specific membrane  
465 antigen targeted ultrasound microbubbles using bioorthogonal chemistry. *PLoS One*.  
466 2017 May 4;12(5):e0176958.

467

## 468 **7. Figure Legends**

### 469 **Figure 1. Proliferation assay**

470 Proliferation assays were performed at 3 and 24 hours after US irradiation. After 3 hours  
471 of irradiation, both LNCaP and PC-3 showed significant differences at 10 Hz and 100  
472 Hz (all p-values < 0.05), but after 24 hours of irradiation, only 10 Hz showed significant  
473 differences (LNCaP: 10 Hz p=0.035, 100 Hz p=0.676. PC-3: 10 Hz p=0.020, 100 Hz  
474 p=0.056).

475

476

### 477 **Figure 2. Imaging Assessment of Membrane Damage**

478 Double staining, with live cells stained green and dead cells stained red, was used to  
479 evaluate membrane disruption caused by US irradiation, using a fluorescence  
480 microscope at 40x zoom.

481 In both LNCaP cells (Fig A) and PC-3 cells (Fig B), the red stain spread around the  
482 dead cells in the irradiated group. The red color fluoresces in response to DNA,  
483 indicating that cell contents may have been released around the dead cells.

484

**485 Figure 3. Apoptosis Assay**

486 To explore the anti-tumor mechanism of US irradiation, the percent of apoptosis and  
487 necrosis was quantitatively evaluated by flow cytometry. Results showed that the  
488 percentage of necrosis was very limited and apoptosis was predominant. Especially in  
489 LNCaP (A), an increase in late apoptosis was observed immediately after irradiation,  
490 and at 24 hours a significant increase was observed at 100 Hz for early apoptosis, late  
491 apoptosis, and total apoptosis.

492

**493 Figure 4. LDH assay**

494 LDH assays were used to confirm that US irradiation disrupts cell membranes and  
495 releases cell contents. In LNCaP, LDH was predominantly increased compared to  
496 controls (10 Hz:  $p < 0.001$ , 100 Hz:  $p = 0.033$ ), but no significant difference was observed  
497 in PC-3 regardless of PRF.

498

**499 Figure 5. Animal Experiment**

500 (A) LNCaP and PC-3 were subcutaneously implanted in mice and US irradiation was  
501 performed three times a week starting 14 days after administration when tumor  
502 diameters reached 7 mm. Tumor size measurements were performed twice a week.

503

504 (B) Figure shows the change in tumor size over time with treatment, with LNCaP  
505 showing a significant difference at 10 Hz compared to controls ( $p = 0.033$ ) and PC-3  
506 showing a significant difference at 100 Hz compared to controls ( $p < 0.001$ ).

507





508 **Figure 6. H-E stain**

509 H-E staining was performed on excised tumor cells and the areas of necrotic tissue were  
510 analyzed for comparison. Although the comparison of tumor size showed significant  
511 differences at 10 Hz for LNCaP and 100 Hz for PC-3, the area of necrotic tissue was  
512 significantly increased in H-E staining, independent of PRF ( $p < 0.001$ , respectively).

513

514 **Figure 7. Immunohistochemical analysis**


515 Three types of immunohistochemistry staining were performed on the excised tumors.  
516 Ki-67 expression, as a cell proliferation marker, showed proliferation was significantly  
517 suppressed at 100 Hz in both LNCaP and PC-3 and 10 Hz in PC-3. Caspase-3  
518 expression, as an apoptosis marker, was significantly elevated in both LNCaP and PC-3  
519 independent of PRF. CD31 expression, as a marker of angiogenesis, was also  
520 significantly suppressed in both LNCaP and PC-3 independent of PRF.




\*:P<0.05

**(A) LNCaP**


ctrl



10 Hz




100 Hz




**(B) PC-3**


ctrl




10 Hz




100 Hz




# (A) LNCaP




**PRF: 10Hz, 0 hour**



**PRF: 10Hz, 24hours**



**PRF: 100Hz, 0 hour**




**PRF: 100Hz, 24 hours**


\*:P<0.05

\*\* :P<0.001


## (B) PC-3




PRF: 10Hz, 0 hour



PRF: 10Hz, 24 hours





PRF: 100Hz, 0 hour





PRF: 100Hz, 24 hours

\*:P<0.05


\*\* :P<0.001





**LNCaP**


\*:P<0.05




**PC3**

\*\* :P<0.001


(A) LNCaP



Control




10 Hz




100 Hz


(B) PC-3



Control




10 Hz




100 Hz

(C)



(D)






(A) LNCaP

Control




10Hz

100Hz




Ki-67



Caspase-3



CD31






(B) PC-3

Control




10Hz

100Hz




Ki-67




Caspase-3



CD31



### (C) LNCaP



### (D) PC-3

